The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA ...Middle East

CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) was accepted for...

Hence then, the article about the snda for sacituzumab tirumotecan sac tmt in combination with pembrolizumab as first line treatment for pd l1 positive nsclc accepted for review by nmpa was published today ( Friday 08/05/2026 - 01:43 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA )

Also on site :

• UCSD, San Diego State part of widespread attack on Canvas education platform
• Sacramento State caught in nationwide cyberattack targeting online learning platform
• Hackers irrumpen en Canvas y afectan a universidades en plena semana de exámenes